BJ's Wholesale Club Hldgs 주식 (NYSE: BJ)

에 대한 최신 뉴스 BJ's Wholesale Club Hldgs (NYSE:BJ) 주식

BJ's Wholesale Club

BJ's Wholesale serves as one of the few warehouse club chains in the United States. Its 250 warehouses are primarily located along the East Coast, most prominently in the New England area. Similar to its warehouse club peers, BJ's charges annual membership fees and keeps costs down by operating a "no-frills" store environment. The company limits the use of distribution centers where possible and stores inventory on pallets directly on the sales floor, often in bulk quantities. The company also offers a limited assortment of 7,000 stock-keeping units at its warehouses to achieve greater procurement scale on select items. About 80% of BJ's net sales come from grocery items and general merchandise, with the remaining 20% coming from gasoline and other ancillary services.

BJ's Wholesale Club Hldgs

Fear and Greed

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 하락했음을 보여 주었지만, 지수는 수요일에 &#34;탐욕&#34; 영역에 머물렀다.미국 주식은 수요일에 하락세로 마감했으며, 다우존스 지수는 세션 중에 800포인트 이상 하락했다. 투자자들은 재정 정책에 대한 우려가 다시 커지면서 조심스러운 태도를 유지했다.

실적 약세와 재정 우려 속 다우 지수 800p 이상 하락: 투자 심리 약화, 공포 지수는 &#39;탐욕&#39; 영역

Feb,19,,2020,San,Mateo, - ,Ca, - ,Usa,-

SNOW

목요일(22일) 아침 미국 지수 선물이 소폭 상승세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 목요일 주목해야 할 주식: BJ홀세일 클럽, 줌 커뮤니케이션스, 아날로그 디바이스, 스노우플레이크 및 윌리엄스 소노마

목요일 주목해야 할 주식: BJ홀세일 클럽, 줌 커뮤니케이션스, 아날로그 디바이스, 스노우플레이크 및 윌리엄스 소노마

What Could Have Been

Analyst Color

Equities

Analyst Ratings

General

BBWI

COST

CURV

FIGS

FIVE

GOOS

LULU

ORLY

ULTA

VSCO

목요일(3일) 골드만삭스의 애널리스트 브룩 로치는 미국의 상호관세가 소매업체에 미치는 영향에 대해 논의했다. 4월 2일, 트럼프 대통령은 멕시코와 캐나다를 제외한 모든 국가에 10% 인상을 포함한 상호 관세와 무역 적자가 있는 일부 국가에 대한 높은 관세율을 발표했다. 

골드만삭스 &#34;관세는 어패럴 및 홈퍼니싱 업계에 제일 큰 타격 줄 것&#34; 경고...가장 취약한 주식은?

BJ's Wholesale Club Holdings, Inc. Common Stock

BJ's Wholesale Club Holdings Inc

PT Bank Jago Tbk

Innovator U.S. Equity Buffer ETF - January

BEIJING CAP INTL ARPRT H by Beijing Capital International Airport Co., Ltd.

Beijing Capital International Airport Co Ltd

BEIJING CAP IN A UNSP/ADR by Beijing Capital International Airport Co., Ltd.

Bluejay Diagnostics Inc

BEIJING GAS BLUE SKY HLDG by BEIJING GAS BLUE SKY HLDGS LTD.

Beijing Gas Blue Sky Holdings Ltd

BEIJING ENTRPR HLDG ORD by Beijing Enterprises Holdings Ltd.

Beijing Enterprises Holdings Ltd

VanEck Gaming ETF

BJ's Restaurants Inc

Sports Toto Bhd

BEIJING TONG REN TANG by Beijing Tong Ren Tang Chinese Medicine Co Ltd, Hong Kong

Beijing Tong Ren Tang Chinese Medicine Co Ltd

Innovator U.S. Equity Buffer ETF - July

Innovator U.S. Equity Buffer ETF - June

BONJOUR HOLDINGS LTD NEW by Bonjour Holdings Ltd.

Bonjour Holdings Ltd

BONJOUR HOLDINGS LTD by Bonjour Holdings Ltd.

BEIJING ENTERPRS WTR GRP by Beijing Enterprises Water Group, Ltd.

Beijing Enterprises Water Group Ltd

BEIJING ENTERPRS WTR ADR by Beijing Enterprises Water Group, Ltd.

In a world where the go-to buzzword is &#8220;disruption,&#8221; <a href="https://www.benzinga.com/etfs">one new ETF </a>is doubling down on the established players. 
Strategy Shares, in conjunction with Rareview Capital LLC, debuted the Monopoly ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MPLY#BATS">MPLY</a>) on May 16, a thematic fund focused on firms with deep market roots, or to use the parlance of the fund, &#8220;monopolistic attributes.&#8221;
Since its launch, the fund&#8217;s offering has been hit with a mix of curiosity and goal-oriented focus. Whereas most money is pursuing innovation, growth-at-all-costs, or the next breakout theme, MPLY pursues safety in dominance instead. 
Its investment thesis relies on four characteristic attributes: • Established brand dominance • Regulatory exclusivity • High entry barriers • No direct competition or limited direct competition. 
That is to say, businesses that don&#8217;t merely compete but effectively set the rules of the game.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/05/45574609/palantir-among-key-picks-as-blackrock-launches-active-defense-industrials-etf">Palantir Among Key Picks As BlackRock Launches Active Defense Industrials ETF</a>
<h1 class="wp-block-heading">Structure And Strategy</h1>
MPLY will have 75 to 125 holdings, diversified among sectors and sizes, with some degree of diversification despite focusing on monopolistic characteristics. Per the guidelines of the fund, the portfolio will not include regulated utilities, presumably a tip of the hat to the avoidance of price-control-subject sectors that may limit returns regardless of monopolistic market position.
<h1 class="wp-block-heading">A Defensive Play In A Volatile Market</h1>
Rareview Capital CIO Neil Azous highlighted the fund&#8217;s possible status as a &#8220;core solution&#8221; within equity portfolios. 
&#8220;MPLY can be a core solution and a potential replacement for a portion of a portfolio's stock market exposure. The Fund seeks to capture market upside, but may act more defensive on the downside,&#8221; Azous said. 
&#8220;The companies the fund invests in generally have sustainable competitive advantages, tangible barriers to entry, and defensive earnings streams. As a result, they typically have the potential to generate high returns on invested capital that may compound over long periods,&#8221; Azous added. 
That means the type of reliability investors seek amid uncertainty in markets: high returns on capital, compounded over time.
Essentially, MPLY is not merely about market dominance, it&#8217;s about foresight in an increasingly story-oriented market. By focusing on long-term moats instead of short-term momentum, the fund offers a defensive growth approach that might appeal to institutional investors as well as individual investors hesitant to overexpose themselves to story stocks.
<h1 class="wp-block-heading">Beyond The Buzz</h1>
While the marketing of the fund emphasizes a compelling mix of defense and innovation, invoking &#8220;Monopoly&#8221; as a branding gimmick is interesting. The label brings to mind the classic board game, as well as a genuine economic entity, so exposed to regulators. Still, the managers are sensitive to delineate their holdings as companies with &#8220;monopolistic qualities,&#8221; but not as so-called monopolies, a semantic, but possibly regulatory, distinction.
The true test will come in the doing: whether MPLY can balance its audacious thesis with strong performance through market cycles. For now, it presents a sharp proposition, betting not on something trendy and new, but on something big that is already dominating the board.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45574690/nvidia-amd-and-the-ai-arms-race-3-explosive-etfs-to-watch-right-now">Nvidia, AMD And The AI Arms Race: 3 Explosive ETFs To Watch Right Now</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

MPLY

Strategy Shares Rolls The Dice With Monopoly ETF For Market Giants

CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) has outperformed the market over the past 5 years by 1.97% on an annualized basis producing an average annual return of 16.25%. Currently, CenterPoint Energy has a market capitalization of $24.24 billion. 
Buying $100 In CNP: If an investor had bought $100 of CNP stock 5 years ago, it would be worth $212.35 today based on a price of $37.14 for CNP at the time of writing.
<h3>CenterPoint Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747952112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In CenterPoint Energy 5 Years Ago Would Be Worth Today

Heritage Commerce Corp (NASDAQ:<a href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) ("Heritage" or "Company"), parent company of Heritage Bank of Commerce (the "Bank"), a premier community business bank, today announces the appointment of Julianne Biagini-Komas as Chair of the Board of Directors (the "Board"), replacing Chairman Jack W. Conner who has assumed the role of Chair Emeritus and has indicated he intends to remain on the Board to provide a smooth and orderly transition through October 2025. Ms. Biagini-Komas, a Certified Public Accountant, has served as Vice Chair of the Board since October 2024, as a director since 2014 and as the Chair of the Audit Committee since 2020.

Management

HTBK

Heritage Commerce Corp Appoints Julianne Biagini-Komas As New Chair Of The Board, Succeeding Jack W. Conner

WIIM

Nuveen Arizona Dividend Advantage Municipal Funds 3

OKLO

Shares of nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday.

KBR(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>), a leader in human spaceflight expertise for more than 60 years, has signed a letter of intent with ACMI Properties to grow KBR's commercial space capabilities including a human spaceflight food laboratory at NASA's Exploration Park, adjacent to Johnson Space Center. The 45,000 square-foot, Houston-based facility would serve the growing commercial low-Earth orbit (LEO) industry where tailorable astronaut food systems and solutions will be designed, tested, validated, produced, and integrated into customer mission environments.

Contracts

KBR Signs LOI With ACMI Properties To Expand Commercial Space Capabilities With New Human Spaceflight Food Laboratory At NASA's Exploration Park Near Johnson Space Center

In the last three months, 37 analysts have published ratings on NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">19</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NVIDIA and provided 12-month price targets. The average target is $172.3, accompanied by a high estimate of $220.00 and a low estimate of $100.00. Experiencing a 3.85% decline, the current average is now lower than the previous average price target of $179.19. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951279_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of NVIDIA by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$150.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NVIDIA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NVIDIA compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NVIDIA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NVIDIA's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NVDA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NVIDIA analyst ratings.</a>
<h2>Delving into NVIDIA's Background</h2>
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
<h3>Financial Insights: NVIDIA</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: NVIDIA displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 77.94%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: NVIDIA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 56.17% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 30.42%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): NVIDIA's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 21.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: NVIDIA's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVDA

The Analyst Verdict: NVIDIA In The Eyes Of 37 Experts

15 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.6, with a high estimate of $63.00 and a low estimate of $20.00. Highlighting a 23.39% decrease, the current average has fallen from the previous average price target of $43.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951268_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Tandem Diabetes Care is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tandem Diabetes Care. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tandem Diabetes Care compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Tandem Diabetes Care's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tandem Diabetes Care's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TNDM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tandem Diabetes Care analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Tandem Diabetes Care</h2>
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Tandem Diabetes Care displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 22.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -55.69%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Tandem Diabetes Care's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -62.41%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.82%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.18, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TNDM

Where Tandem Diabetes Care Stands With Analysts

Throughout the last three months, 8 analysts have evaluated Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Moderna, revealing an average target of $37.62, a high estimate of $70.00, and a low estimate of $26.00. Observing a downward trend, the current average is 16.94% lower than the prior average price target of $45.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951259_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Moderna. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$32.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Moderna's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Moderna's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Moderna analyst ratings.</a>
<h2>Get to Know Moderna Better</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Understanding the Numbers: Moderna's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Moderna's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -35.93%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Moderna's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -907.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Moderna's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.26%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Moderna's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Moderna's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRNA

Where Moderna Stands With Analysts

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) has outperformed the market over the past 5 years by 3.02% on an annualized basis producing an average annual return of 17.31%. Currently, IBM has a market capitalization of $240.71 billion. 
Buying $1000 In IBM: If an investor had bought $1000 of IBM stock 5 years ago, it would be worth $2,221.57 today based on a price of $259.00 for IBM at the time of writing.
<h3>IBM's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747951252_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In IBM 5 Years Ago Would Be Worth This Much Today

In the last three months, 4 analysts have published ratings on Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Vericel, presenting an average target of $59.75, a high estimate of $67.00, and a low estimate of $51.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.27%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951247_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vericel. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vericel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vericel compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vericel's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vericel's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VCEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vericel analyst ratings.</a>
<h2>Discovering Vericel: A Closer Look</h2>
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
<h3>A Deep Dive into Vericel's Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Vericel's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 2.57%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vericel's net margin is impressive, surpassing industry averages. With a net margin of -21.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Vericel's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.83%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Vericel's ROA excels beyond industry benchmarks, reaching -2.62%. This signifies efficient management of assets and strong financial health.
Debt Management: Vericel's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.33.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VCEL

What Analysts Are Saying About Vericel Stock

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ZTO Express (Cayman) and provided 12-month price targets. The average target is $21.65, accompanied by a high estimate of $23.00 and a low estimate of $19.00. A 13.85% drop is evident in the current average compared to the previous average price target of $25.13. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951234_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of ZTO Express (Cayman)'s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu Xu</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.60</td>
<td>$26.40</td>
</tr>
<tr>
<td>Fan Tso</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Parash Jain</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Lin Chen</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ZTO Express (Cayman). This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ZTO Express (Cayman) compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ZTO Express (Cayman)'s future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ZTO Express (Cayman)'s market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ZTO Express (Cayman) analyst ratings.</a>
<h2>Unveiling the Story Behind ZTO Express (Cayman)</h2>
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 22.1% in 2022. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 77% voting rights as of June 30, 2023. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 11.7% interest.
<h3>A Deep Dive into ZTO Express (Cayman)'s Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, ZTO Express (Cayman) showcased positive performance, achieving a revenue growth rate of 21.66% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 19.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ZTO Express (Cayman)'s ROE excels beyond industry benchmarks, reaching 4.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ZTO Express (Cayman)'s financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where ZTO Express (Cayman) Stands With Analysts

In the current session, the stock is trading at $195.96, after a 2.19% spike. Over the past month, Taiwan Semiconductor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) stock increased by 19.50%, and in the past year, by 22.62%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1747951224_0.png" alt="Past Year Chart" />

<h3>How Does Taiwan Semiconductor P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 153.45 in the Semiconductors &amp; Semiconductor Equipment industry, Taiwan Semiconductor Inc. has a lower P/E ratio of 23.19. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747951224_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Taiwan Semiconductor

Ratings for e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $82.0, a high estimate of $100.00, and a low estimate of $59.00. Observing a downward trend, the current average is 8.64% lower than the prior average price target of $89.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1747951220_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive e.l.f. Beauty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bill Chappell</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$85.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to e.l.f. Beauty. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of e.l.f. Beauty compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for e.l.f. Beauty's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of e.l.f. Beauty's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on e.l.f. Beauty analyst ratings.</a>
<h2>Discovering e.l.f. Beauty: A Closer Look</h2>
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.
<h3>Understanding the Numbers: e.l.f. Beauty's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: e.l.f. Beauty's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 31.14%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.
Net Margin: e.l.f. Beauty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): e.l.f. Beauty's ROE stands out, surpassing industry averages. With an impressive ROE of 2.31%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.38%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.4, e.l.f. Beauty adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing e.l.f. Beauty: Insights From 12 Financial Analysts

PDSB

PDS Biotechnology shares are trading higher after the company announced phase 2 versamune HPV with pembrolizumab shows median overall survival of 39.3 months in CPS ≥20 patients with recurrent/metastatic HPV16-positive head and neck cancer.

VSTM

Verastem Oncology shares are trading higher after the company announced phase 2 dose level 1 shows 83% overall response rate in frontline metastatic pancreatic ductal adenocarcinoma.

Selected recommended Phase 2 dose: Dose level 1 demonstrated an ORR of 83% (10/12) in frontline metastatic pancreatic ductal adenocarcinoma
Plans for registrational Phase 3 study underway in frontline metastatic pancreatic ductal adenocarcinoma
Company will host an R&amp;D investor webcast on Monday, June 2 at 11:00 am CDT to review the updated RAMP 205 data as well as updated data on VS-7375 presented at ASCO
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1 cohort, which was selected as the recommended Phase 2 dose (RP2D), achieved an overall response rate (ORR) of 83% (10/12).
The Company will host a research and development (R&amp;D) investor webcast on Monday, June 2 at 11:00 am CDT to review the full updated data from RAMP 205 and the updated data from the Phase 1/2 study in China of VS-7375 (also known as GFH375), an oral KRAS G12D (ON/OFF) inhibitor, by partner GenFleet Therapeutics that will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 2, 2025.

Biotech

Verastem Oncology's Phase 2 Dose Level 1 Shows 83% Overall Response Rate In Frontline Metastatic Pancreatic Ductal Adenocarcinoma

<a href="https://www.reuters.com/business/energy/trump-sign-orders-boost-nuclear-power-soon-friday-sources-say-2025-05-22/" title="https://www.reuters.com/business/energy/trump-sign-orders-boost-nuclear-power-soon-friday-sources-say-2025-05-22/">https://www.reuters.com/business/energy/trump-sign-orders-boost-nuclear-power-soon-friday-sources-say-2025-05-22/</a>

'Trump to sign orders to boost nuclear power as soon as Friday, sources say'- Reuters

PDS Biotechnology's Phase 2 Versamune HPV With Pembrolizumab Shows Median Overall Survival Of 39.3 Months In CPS ≥20 Patients With Recurrent/Metastatic HPV16-Positive Head And Neck Cancer; Phase 3 Trial Enrolling, Data To Be Discussed In Upcoming Conference Call Ahead Of ASCO 2025 Presentation

Watching U.S. Steel Corp; Reuters Cites Person Familiar With The Matter Saying, Trump Will Review CFIUS Recommendations On Nippon Steel Deal; Majority Of CFIUS Member Agencies Believe Any National Security Risks Posed By The Deal Can Likely Be Addressed Through Mitigation; CFIUS Agencies Were Not Unanimous In Their Recommendation To Trump On National Security Implications Of Deal

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 10.66% on an annualized basis producing an average annual return of 22.46%. Currently, Regeneron Pharmaceuticals has a market capitalization of $64.44 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,139.25 today based on a price of $596.85 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747950317_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Press Releases

Shopping at BJ's Wholesale Club Is More Convenient Than Ever with Tap & Pay at all BJ's Gas Locations

BJ's Wholesale Club to Open in Brooksville, Florida, on February 21

BJ's Wholesale Club Myrtle Beach Location Set to Open February 28

BJ's Wholesale Club Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2024 Results

BJ's Wholesale Club Announces Expansion into Texas as Part of Plan to Add 25-30 New Clubs Over Next Two Fiscal Years

BJ's Wholesale Club Announces March 7 for Grand Opening of Southern Pines Location

BJ's Wholesale Club to Open 25th New Jersey Location in Whippany on March 21

April 25 Set as Grand Opening Date for BJ's Wholesale Club in Staten Island

BJ's Wholesale Club Announces First Quarter Fiscal 2025 Earnings Conference Call Date

BJ's Wholesale Club Holdings, Inc. Announces First Quarter Fiscal 2025 Results

Costco Wholesale Corporation - Common Stock

Costco Wholesale

Dada Nexus Limited - American Depositary Shares

Dada Nexus

Dollar General

Dollar Tree

Pricesmart

Target

Walmart

JP Morgan

Citigroup

Evercore ISI Group

Goldman Sachs

Screenshot 2024-06-24 at 5.31.08 PM

Emerging Markets

Movers & Shakers

IZEA

Influencers Are Driving Consumers To Discount Clubs And Major Retailers Like Costco Finds IZEA&#39;s Latest Survey

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 하락했음을 보여 주었지만, 지수는 수요일에 &#8220;탐욕&#8221; 영역에 머물렀다.
미국 주식은 수요일에 하락세로 마감했으며, 다우존스 지수는 세션 중에 800포인트 이상 하락했다. 투자자들은 재정 정책에 대한 우려가 다시 커지면서 조심스러운 태도를 유지했다.
로우스 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)는 2025 회계연도 1분기에 엇갈린 실적을 발표했으며 타깃(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)은 예상보다 약한 1분기 실적을 발표했다.
경제 데이터 측면에서, 미국의 모기지 신청 건수는 5월 16일로 끝나는 주에 전주 대비 5.1% 감소했다.
S&amp;P 500 지수 대부분의 섹터는 하락 마감했고 특히 부동산, 헬스케어, 금융 섹터가 수요일에 가장 큰 손실을 기록했다. 그러나 통신 서비스 섹터는 전반적인 시장 추세에 반하여 세션을 상승세로 마감했다.
다우존스는 수요일에 약 817포인트 하락하여 41,860.44포인트로 마감했다. S&amp;P 500은 1.61% 하락하여 5,844.61포인트, 나스닥 종합지수는 1.41% 하락하여 18,872.64포인트로 마감했다.
투자자들은 오늘 BJ홀세일 클럽 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>), 아날로그 디바이스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>), 윌리엄스 소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 66.2의 수치를 기록하며, 수요일에 &#8220;탐욕&#8221; 영역에 머물렀다. 이전 수치는 68.7이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

실적 약세와 재정 우려 속 다우 지수 800p 이상 하락: 투자 심리 약화, 공포 지수는 '탐욕' 영역

목요일(22일) 아침 미국 지수 선물이 소폭 상승세를 보이는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다.
<ul class="wp-block-list">
<li>BJ홀세일 클럽 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>): 목요일 개장 전 실적을 발표할 예정이다. 주당순이익 91센트, 매출 52억 달러가 예상된다. 주가는 수요일 애프터마켓에서 0.2% 상승하여 117.73달러에 거래되었다.</li>
<li>줌 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>): 수요일 폐장 후 1분기 예상보다 강한 실적을 발표했다. 또한 2026회계연도 조정 주당순이익 가이던스를 5.34달러에서 5.37달러로, 그리고 5.56달러에서 5.59달러로 상향 조정했으며, 애널리스트 예상치 5.41달러를 초과하는 수준이다. 또한 매출 가이던스는 47억 9천만 달러에서 48억 달러에서 48억 1천만 달러로 상향 조정했으며, 예상치 47억 9천만 달러를 초과했다. 주가는 수요일 애프터마켓에서 0.2% 하락한 82.14달러에 거래되었다.</li>
<li>아날로그 디바이스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>): 목요일 개장 전 실적을 발표할 예정이다. 주당순이익 1.70달러, 매출 25억 1천만 달러가 예상된다. 주가는 수요일 애프터마켓에서 1.3% 상승한 225.00달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인해보세요
<ul class="wp-block-list">
<li>스노우플레이크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>): 1분기 예상보다 좋은 실적과 매출 결과를 발표했다. 또한 2분기 제품 매출이 10억 3,500만 달러에서 10억 4,000만 달러 범위에 이를 것으로 예상하며, 이는 전년 대비 약 25% 증가하는 수치다. 그리고 연간 제품 매출이 43억 3천만 달러에 이를 것으로 예상하며, 이는 전년 대비 25%의 성장률을 나타낸다. 주가는 수요일 애프터마켓에서 7.5% 상승하여 192.50달러에 거래되었다.</li>
<li>윌리엄스 소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>): 목요일 개장 전 실적을 발표할 예정이다. 주당순이익 1.76달러, 매출 16억 7천만 달러가 예상된다. 주가는 수요일 애프터마켓에서 0.1% 하락하여 167.80달러에 거래되었다.</li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일(3일) 골드만삭스의 애널리스트 브룩 로치는 미국의 상호관세가 소매업체에 미치는 영향에 대해 논의했다.
4월 2일, 트럼프 대통령은 멕시코와 캐나다를 제외한 모든 국가에 10% 인상을 포함한 상호 관세와 무역 적자가 있는 일부 국가에 대한 높은 관세율을 발표했다.
브룩 로치는 베트남, 인도네시아, 방글라데시, 캄보디아와 같은 주요 소싱 파트너에 대한 관세 인상으로 인해 소매업에 가장 큰 영향을 미칠 것으로 예상했다.
미국은 수입품에 대한 관세를 대폭 인상하고 있으며, 중국의 관세율은 20%에서 54%로 인상될 예정이다. 베트남(46%), 인도네시아(32%), 방글라데시(37%), 캄보디아(49%), 인도(27%) 등 다른 주요 공급국도 관세가 인상되며, EU 수입품에는 20%의 관세가 부과된다.
캐나다와 멕시코는 미국-멕시코-캐나다 협정(USMCA)에 따라 면세 대상이지만, USMCA를 준수하지 않는 상품에는 12%의 세금이 부과된다. 전반적으로 의류 및 신발 관세는 평균 38%까지 상승할 것으로 예상된다고 로치는 지적했다.
또한 중국과 홍콩에서 출발하는 800달러 미만의 패키지에 대한 최소 면세 혜택은 2025년 5월 1일에 종료된다.
이러한 배송에는 30% 또는 품목당 25달러의 관세가 부과되며, 2025년 6월 1일 이후에는 품목당 50달러로 인상된다. 미국 상무장관은 90일 이내에 이 정책을 마카오로 확대할지 여부를 검토할 예정이다.
새로 발표된 관세는 브랜드와 소매업체를 압박하여 가격을 조정하고, 공급업체와 협상하고, 마진을 보호하기 위해 비용을 최적화하도록 강요할 것이다.
대부분의 회사가 영향을 받을 것이지만, 미국 내 판매 노출이 적은 브랜드들은 상대적으로 덜 노출될 것이다. 아머 스포츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>), 캐나다 구스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>), PVH(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) 같은 브랜드들이 이에 해당한다. 백화점 및 저가 소매업체와 같은 간접 조달을 하는 소매업체들은 공급망의 혼란으로부터 이익을 볼 수 있다.
국제 시장에서 제품을 조달하지 않거나 면세 지역에서 조달하는 기업들은 세이버스 밸류 빌리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>)의 중고 비즈니스 모델과 콘투어 브랜드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>)가 멕시코에 의존하고 있지만 방글라데시에서도 조달한다는 점에서 덜 노출된다.
로치는 모멘텀과 강한 소비자 참여를 가진 브랜드들이 전반적으로 시장에서 더 큰 상대적 가격 권력을 가질 가능성이 높다고 언급했다.
베트남과 캄보디아에 노출된 기업들이 새로운 관세에 더 높은 노출을 가지며, 여기에는 스포츠웨어인 룰루레몬 애슬레티카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>), 나이키(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), 일반 의류인 토리드 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>), 피그스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>), 빅토리아 시크릿(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>), 갭(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)이 포함된다.
홈퍼니싱 업계는 RH(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>)와 윌리엄스 소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) 같은 회사들이 중국과 베트남에 높은 노출로 인해 관세의 가장 큰 위험에 직면하고 있다.
RH는 아시아에서 72%의 제품을 조달하며, 그중 23%는 중국, 35%는 베트남에서 온다. 윌리엄스 소노마는 23%의 중국과 14%의 베트남 노출을 보유한다.
소매업체인 파이브 블로우(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>)와 베스트바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)도 취약하며, 이들의 제품 60%가 중국에서 조달된다. 베트남 노출이 대부분의 산업에서 불확실한 반면, 홈 퍼니싱 회사들은 가장 높은 위험을 가진다고 했다.
반면 어드밴스 오토 파츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>), 오토존(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>), 오레일리 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) 같은 자동차 부품 회사 및 홈 디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), 로우스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) 같은 주택 개선용품 소매업체는 비용 증가를 전가할 수 있기 때문에 더 나은 위치에 있다.
유사하게, 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), BJ's 홀세일 클럽 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>), 코스트코(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) 같은 식료품 소매업체들은 상대적으로 안전하다.
중국에 대한 의존도가 최소인 기업들, 예를 들어 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)와 배스앤바디웍스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)도 이러한 관세에 대해 잘 대비하고 있다.
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

골드만삭스 "관세는 어패럴 및 홈퍼니싱 업계에 제일 큰 타격 줄 것" 경고...가장 취약한 주식은?

지난주 가장 좋은 성과를 보인 대형주 10개는 다음과 같다.
<ol>
<li>옥타 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>): 회사가 <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44108947/okta-stock-is-surging-tuesday-heres-why" target="_blank" rel="noreferrer noopener">예상보다 나은</a> 4분기 재무 실적을 발표하고, 여러 애널리스트가 <a href="https://www.benzinga.com/quote/BJ/analyst-ratings" target="_blank" rel="noreferrer noopener">주식 평가를 상향 조정하고 목표주가를 올린</a> 후 24.26% 상승했다.</li>
<li>아르셀로미탈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>): 금과 은의 강세로 19.50% 상승했다.</li>
<li>ING 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ING#NYSE">ING</a>): 회사가 7,000만 유로 규모의 자사주 매입 프로그램을 발표한 후 16.98% 상승했다.</li>
<li>포스코 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKX#NYSE">PKX</a>): 전체 시장의 강세와 트럼프 대통령이 자동차 관세를 연기할 것이라는 보도로 인해 15.55% 상승했다.</li>
<li>모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): 스테판 반셀(Stephane Bancel) CEO가 주식 매입을 공개한 후 15.02% 상승했다.</li>
<li>엘빗 시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>): 14.80% 상승했다.</li>
<li>BJ&#8217;s 홀세일 클럽 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>): 회사가 예상치를 상회하는 <a href="https://www.benzinga.com//node/44165337" target="_blank" rel="noreferrer noopener">4분기 재무 실적</a>을 발표한 후 14.06% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/BJ/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정했다.</a></li>
<li>로켓 컴퍼니스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>): 12.64% 상승했다.</li>
<li>트립닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>): 중국이 2025년 GDP 성장 목표를 약 5%로 설정하고 경기 부양 조치를 발표했다고 보도한 후 12.61% 상승했다.</li>
<li>스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): 비트코인 (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격이 <a href="https://www.benzinga.com//node/44138476" target="_blank" rel="noreferrer noopener">9만 달러에 가까워졌다</a>는 소식으로 12.43% 상승했다.</li>
</ol>
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Large Cap

Movers

$BTC

ESLT

MSTR

OKTA

TCOM

옥타·모더나·스트레티지 등 지난주 급등한 대형주 10종목 (3월 3일~7일)

목요일(6일) 아침 미국 주식 선물이 하락하는 가운데, 투자자들의 관심을 끌 수 있는 주식들이 다음과 같다.
<ul>
<li>BJ's 홀세일 클럽 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>): 분기 주당순이익 88센트, 매출 53억 2천만 달러로 예상하고 있다. 수요일 애프터마켓에서 주식은 0.1% 하락하여 100.06달러에 거래되었다.</li>
<li>크로거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>): 목요일 개장 전 실적을 발표할 예정이며, 분기 주당순이익 1.11달러, 매출 345억 1천만 달러로 예상한다. 수요일 애프터마켓에서 주식은 0.27% 하락한 62.36달러에 거래되었다.</li>
<li>비바 시스템즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>): 4분기 매출이 7억 2,090만 달러로 전년 대비 14% 증가했다고 보고했다. 이라한 매출은 애널리스트들이 예상한 6억 9,911만 달러를 초과한 수치다. 회사는 전체 회계연도 매출 가이던스를 30억 4천만 달러에서 30억 5천 5백만 달러 사이로 제시했으며, 애널리스트 예상치 30억 5천 5백만 달러와 일치한다. 회사는 전체 연도 주당순이익(EPS)을 7.32달러로 전망했고, 이는 애널리스트 예상치 6.91달러를 초과하는 수치다. 주식은 수요일 애프터마켓에서 7.16% 상승한 235.69달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>메이시스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>): 목요일 개장 전 실적을 발표할 예정이며, 분기 주당순이익 1.53달러, 매출 78억 7천만 달러로 예상된다. 주식은 수요일 애프터마켓에서 0.5% 상승한 13.37달러에 거래되었다.</li>
<li>휴렛 팩커드 엔터프라이즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>): 목요일 폐장 후 실적을 발표할 예정이며, 분기 주당순이익 49센트 매출 78억 2천만 달러로 예상된다. 주식은 수요일 애프터마켓에서 0.3% 상승한 18.89달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

VEEV

목요일 주목해야 할 주식: 크로거, BJ's 홀세일 클럽, 비바 시스템즈, 메이시스 및 휴렛 팩커드 엔터프라이즈

소매업체들은 역대 가장 바쁜 블랙 프라이데이 쇼핑 주말 동안 온라인과 매장에서 증가된 트래픽을 경험했다. BofA 증권의 분석가들은 소매 부문의 <a href="https://www.benzinga.com/24/12/42265010/amazon-and-walmart-dominate-black-friday-as-online-sales-soar-146">초기 홀리데이 승자들에 대해 언급</a>했다.
전자 상거래: 어도비 애널리틱스에 따르면, 추수감사절과 블랙 프라이데이 동안 온라인 매출이 각각 9%와 10% 증가하여 2023년 수준을 초과했다. BofA 증권의 분석가들은 인공지능(AI) 쇼핑 어시스턴트의 사용이 31% 증가하고, AI 서비스를 제공하는 사이트에서 전환율이 9% 증가한 점을 강조했다.
더 알아보기: <a href="https://www.benzinga.com/etfs/new-etfs/24/12/42270723/new-conservative-etf-aims-to-invest-in-sp-500-without-dei-were-going-to-deliver-that-mandate">새로운 보수적 ETF가 DEI 없이 S&amp;P 500에 투자하는 것을 목표로 합니다: ‘우리는 그 임무를 수행할 것입니다'</a>
분석가들은 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)과 웨이페어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>)와 같은 소매업체들이 가치와 더 빠른 배송 속도에 집중하여 전자상거래 부문에서 강한 성장을 다시 이끌어내고 있다고 강조했다. 특히 메이크업과 스킨케어, 스마트워치, 해리포터와 위키드 프랜차이즈의 영화 관련 상품이 인기 카테고리로 꼽혔다.
매장 내: BofA 증권은 네 개 주에서 매장 내 조사를 실시하고, 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), 타깃(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) 및 아카데미 스포츠 앤 아웃도어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>)를 매장 트래픽에서 &#8220;두드러진&#8221; 업체로 보고했다.
또한, 코스트코 홀세일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>)과 BJ 홀세일 클럽 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>)도 소비자들이 이번 홀리데이 시즌에 가치에 계속 집중하고 있는 점을 고려할 때 혜택을 받을 수 있는 업체로 강조되었다.
전문 소매업체: BofA는 배스 앤 바디 웍스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)를 전문 소매업체 중에서 최고의 홀리데이 추천주로 선정하고, 주식에 대해 매수 등급과 45달러의 목표 주가를 유지했다. 이 리서치 회사는 제품 파트너십과 카테고리 출시로 인한 3분기 매출 성장의 지속을 기대하고 있다.
BofA 등급:
<ul>
<li>타깃 주식에 대해 매수 등급과 160달러의 목표 주가를 유지했다.</li>
<li>아카데미 스포츠 앤 아웃도어에 대해 중립 등급과 63달러의 목표 주가를 유지했다.</li>
<li>월마트 주식에 대해 매수 등급과 105달러의 목표 주가를 유지했다.</li>
<li>아마존 주식에 대해 매수 등급과 230달러의 목표 주가를 유지했다.</li>
<li>코스트코 주식에 대해 매수 등급과 962달러의 목표 주가를 유지했다.</li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AMZN

월마트, 타깃 및 배스 앤 바디 웍스, 블랙 프라이데이에서 우승자로 부상: 분석가들

대통령 당선인 도널드 트럼프가 멕시코와 캐나다에서 수입하는 제품에 25%의 관세를 부과하고, 중국 제품에는 10%의 추가 <a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention" target="_blank" rel="noopener" data-google-interstitial="false">관세를 부과하겠다</a>고 제안했다.
이는 상당한 관세를 부과하는 것으로, 투자자들에게는 2019년 무역 전쟁으로 돌아가는 것을 의미할 수 있지만, 이번에는 상황이 더 심각하고 경제적 배경이 불안정하다.
JP모건의 애널리스트인 크리스토퍼 호버스(Christopher Horvers)는 관세 압박이 지금은 첫 번째 관세 분쟁 때보다 더 견디기 힘들 수 있다고 경고하고 있다. 이미 인플레이션이 소비자에게 아픈 문제로 자리잡은 상황에서, 소매 및 제조 부문은 가격 결정력의 딜레마에 빠질 수 있다.
압박이 가장 심한 분야와 이것이 주가에 미칠 영향은 다음과 같다.
참고: <a href="https://kr.benzinga.com/news/usa/economy/%EA%B3%A8%EB%93%9C%EB%A7%8C%EC%82%AD%EC%8A%A4-%EC%BA%90%EB%82%98%EB%8B%A4-%EB%8B%AC%EB%9F%AC%EB%A9%95%EC%8B%9C%EC%BD%94-%ED%8E%98%EC%86%8C-%EB%8C%80%EA%B7%9C%EB%AA%A8-%EB%A7%A4%EB%8F%84/" target="_blank" rel="noopener">골드만삭스는 캐나다 달러와 멕시코 페소의 대규모 매도를 예상하며, 트럼프의 관세가 USMCA 협정을 위협한다고 경고</a>
<h2 class="wp-block-heading">전자기기, 장난감, 가구: 관세 문제 지역</h2>
&#8220;중국산&#8221; 라벨은 단순한 태그라인이 아니라 전자기기, 장난감 및 가정용 가구와 같은 분야의 핵심이다. 호버스에 따르면, 소비자 전자기기는 베스트 바이(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NASDAQ">BBY</a>)가 최대 60%를 중국에서 조달하는 등, 가격 인상에 매우 취약하다. 또한, 장난감 대기업인 해즈브로(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>)와 마텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>)은 미국 매출의 50%가 중국산 제품에 의존하고 있다.
소매업체인 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)와 타깃(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)은 미국 장난감 시장의 40%를 점유하고 있어 가격 인상을 소비자에게 전가할 수 있지만, 일정 한도까지이다.
한편, 가정용 가구 업체인 RH(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>)와 윌리엄스-소노마(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>)는 이미 마진 압박을 받고 있어 추가적인 피해를 볼 수 있다.
이런 분산된 산업에서 가격 결정력은 약하고, 추가 비용은 소비자 수요를 저해하거나 이익을 잠식할 수 있다.
<h2 class="wp-block-heading">자동차 부품: 높은 수입 의존도, 그러나 강한 방패</h2>
자동차 부품은 높은 수입 의존도(예: 오토존(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/azo#NYSE">AZO</a>)의 경우 45%)로 취약해 보일 수 있지만, 호버스는 이 부문이 강한 가격 결정력을 지니고 있어 마진 압박에 대한 완충 역할을 할 것이라고 제안한다.
장난감이나 전자기기와 달리, 자동차 부품은 필수 구매 항목이다. 브레이크 교체나 배터리 교환을 건너뛸 수는 없다.
<h2 class="wp-block-heading">식료품점: 낮은 위험, 높은 회복력</h2>
식료품 부문은 유리한 입장을 차지한 것 같다. 낮은 수입 의존도와 강력한 가격 결정력을 지닌 BJ 홀세일 클럽 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>)와 코스트코 홀세일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) 같은 업체들은 대부분 국내 조달과 필요 기반 수요 덕분에 관세에 저항력을 갖춘 요새로 남아 있다.
<h2 class="wp-block-heading">2024년 vs 2019년: 가격 결정력 감소, 고통 공유 증가</h2>
2019년의 관세는 고통스러웠지만 관리 가능한 수준이었다. 이번에는 호버스가 경고하듯, 상황이 다를 수 있다. 소비자들은 이미 2020년 이후 필수품 가격 인상을 겪었고, 소매업체와 제조업체는 대응할 여지가 줄어들었다. 가전제품이나 가구와 같은 고가 소비재는 가격 인상에 소비자들이 주저하게 되어 판매량이 급격히 감소할 수 있다.
또한, 이번 관세는 정치적 요소가 더 강하게 작용하는 것으로 보인다. 호버스는 소비자에게 큰 가격 충격을 주는 것이 역효과를 낳을 수 있다고 믿으며, 특히 인플레이션이 유권자 감정에 영향을 미치는 상황에서 그렇다. 이는 2019년 소비재에 대한 관세가 철회된 사례에서도 명백히 나타났다.
<h2 class="wp-block-heading">투자자들이 주목해야 할 사항</h2>
관세가 시행된다면, 제조업체, 소매업체 및 소비자 간의 고통이 공유될 것이다.
투자자들은 영향을 받는 부문에서 가격 전략, 마진 회복력 그리고 판매량을 주시해야 한다. 공급원이 다양하고 가격 결정력이 강하거나 필수 수요가 있는 주식은 불황을 견뎌낼 수 있는 더 나은 위치에 있다.
트럼프의 관세 2.0은 고위험 협상 전술일 수 있지만, 재량적 수입품에 노출된 주식에 대해서는 무시할 수 없는 위험이다.
무역 긴장이 고조됨에 따라, 투자자들은 관세 비용을 누가 부담하는지 뿐만 아니라 소비자들이 가격 인상에 얼마 동안 견딜 수 있는지도 의문을 제기하고 있다.

다음 내용 읽기: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42058282/trumps-tariffs-could-have-severe-consequences-for-us-defense-sector-beijing-adviser-warns">트럼프의 관세가 미국 방산 부문에 &#8216;심각한 결과&#8217;를 초래할 수 있다고 베이징 고문이 경고</a></li>
</ul>
사진 제공: Khanthachai C, Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Asia

Government

Regulations

Politics

Global

트럼프의 관세 계획, 수입품을 겨냥: 위험에 처한 전자제품 및 소매 주식

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 더욱 개선되었음을 보여주었으며, 수요일(20일) 지수는 &#8220;중립&#8221; 영역에 머물렀다.
수요일 미국 증시는 혼조세를 보인 가운데 다우존스 지수는 장중 100p 이상 상승했다.
타깃(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) 주식은 3분기 실적이 부진하게 나타나고 2024회계연도 전망을 하향 조정한 후 21% 이상 하락했다. 반면, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 수요일 장 마감 후 긍정적인 실적과 매출 결과를 발표했다.
경제지표 측면에서, 미국의 주택담보대출 신청 건수는 11월 15일 주 기준으로 이전 주보다 1.7% 증가하여 0.5% 증가에 비해 상승했다.
S&amp;P 500 지수 대부분 섹터는 긍정적으로 마감되었으며 특히 헬스케어, 에너지 및 원자재 섹터가 가장 큰 상승폭을 기록했다. 그러나 소비재와 금융 섹터는 전체 시장 흐름에 반해 하락세로 마감했다.
다우존스 지수 수요일에 43,408.47포인트로 약 140포인트 상승하여 마감했다. S&amp;P 500 지수는 0.01% 상승한 5,917.11포인트, 나스닥 종합 지수는 0.11% 하락한 18,966.14포인트로 마감했다.
투자자들은 오늘 디어 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), BJ 홀세일 클럽 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>), 인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 50.8의 지수이며 수요일에 &#8220;중립&#8221; 구역에 머물렀다. 이전 수치 49.9 대비 소폭 상승한 수준이다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

INTU

다우 100p 이상 상승, 엔비디아 호실적 발표: 공포·탐욕 지수는 '중립' 영역 유지

목요일(21일) 아침 미국 주식 선물이 혼조세를 보이고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들이 다음과 같다.
1. 디어 앤 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>)
<a href="https://pro.benzinga.com/dashboard">벤징가 프로 데이터</a>에 따르면 월가에서는 오늘 개장 전 실적을 발표할 디어 앤 컴퍼니의 매출은 93억 4천만 달러, 주당순이익은 3.87달러로 예상하고 있다. 시간외 거래에서 0.01% 상승한 405.02달러를 기록했다.
2. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아는 수요일(20일)에 예상보다 나은 3분기 실적을 발표했다. 벤징가 프로의 데이터에 따르면 3분기 매출은 전년 동기 대비 94% 증가한 351억 달러로, 시장 컨센서스 예상치 331억 2,000만 달러를 상회했다.
엔비디아는 4분기 매출이 375억 달러(± 2%)가 될 것으로 예상한다고 밝혔다. 시간외 거래에서 엔비디아 주가는 2.5% 하락한 142.25달러를 기록했다.
3. BJ 홀세일 클럽 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>)
애널리스트들은 개장 전 실적을 발표하는 BJ 홀세일의 매출은 51억 달러, 주당순이익은 91센트로 예상한다. 주가는 시간외 거래서 0.9% 상승한 86.45달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 스노우플레이크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)
스노우플레이크는 예상보다 높은 3분기 실적을 발표했다. 4분기 제품 매출이 전년 동기 대비 약 23% 증가한 9억 6,600만 달러에서 9억 1,100만 달러 사이가 될 것으로 예상하고 있다. 또한 연간 제품 매출 가이던스도 전년 대비 29% 성장한 33억 5,600만 달러에서 34억 3,000만 달러로 상향 조정했다. 시간외 거래에는서 19.8% 상승한 154.70달러를 기록했다.
5. 인튜이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)
오늘 장 마감 후 실적을 발표할 인튜이트의 매출은 31억 4천만 달러, 주당순이익은 2.35달러로 예상된다. 주가는 시간외 거래에서 0.3% 상승한 652.80달러를 기록했다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

BJ's Wholesale Club Hldgs

뉴스

에 대한 최신 뉴스 BJ's Wholesale Club Hldgs (NYSE:BJ) 주식

목요일, 5월 22, 2025

금요일, 4월 04, 2025

일요일, 3월 09, 2025

목요일, 3월 06, 2025

월요일, 12월 02, 2024

수요일, 11월 27, 2024

목요일, 11월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌